GlassScriptPhysician profile
Louise A Kwan
NPI 1730110990
$647.82
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.71 | 2019-2021 | |
| Radius Health, INC. | $121.62 | 2019 | |
| Gilead Sciences, INC. | $113.63 | 2019 | |
| Glaxosmithkline, LLC. | $58.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.80 | 2019 | |
| Melinta Therapeutics, LLC | $18.30 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $17.01 | 2019 | |
| Novo Nordisk INC | $15.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.39 | 2019 | |
| Amarin Pharma, INC. | $14.16 | 2019 | |
| Allergan, INC. | $12.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.55 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louise Kwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.